Hormone Resistant Prostate Cancer Completed Phase 2 Trials for Ipilimumab (DB06186)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01498978Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment